

Duration of corticosteroid treatment in hospitalized COVID-19 patients, less is more

Lucijanić, Marko; Papić, Ivan; Ortner Hadžiabdić, Maja

Source / Izvornik: **The Korean Journal of Internal Medicine, 2024, 39, 360 - 361**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3904/kjim.2023.450>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:098115>

Rights / Prava: [Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-12-04**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)





Duration of corticosteroid treatment in hospitalized COVID-19 patients, less is more

Marko Lucijan^{1,2}, Ivan Papic³, and Maja Ortner Hadziabdic⁴

¹Department of Hematology, University Hospital Dubrava, Zagreb; ²School of Medicine University of Zagreb, Zagreb; ³Department of Pharmacy, University Hospital Dubrava, Zagreb; ⁴Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

Dear Editor,

We have read with great interest the paper by Kim et al. [1] who reported improved survival and no increase in nosocomial complications with prolonged corticosteroid use in severe COVID-19 patients. Since the two groups of corticosteroid users were defined by a post-baseline feature (duration of corticosteroid use > 14 days), there is a high risk of immortalization bias, i.e., patients who died early during hospitalization are automatically classified as short-term corticosteroid users, inevitably biasing the final conclusions. Thus, we aimed to evaluate the same phenomenon in our cohort of severe and critical COVID-19 patients treated in a tertiary level institution, University hospital Dubrava, Zagreb, Croatia in period from March 2020 to June 2021. All patients were Caucasian adults. The majority of deaths occurred during the first 14 days of hospitalization (59.7% of all deaths, median time of death 12 days from admission). Therefore, out of a total of 1,558 available patients, we selected a cohort of 1,129 patients who survived for at least 14 days post-hospital admission and who were treated with corticosteroids. Corticosteroid doses were classified as low doses (below 1 mg/kg body weight, given in 54.6% patients), high doses (1–2 mg/kg body weight, given in 36.8% patients) and very high doses (above 2 mg/kg body weight, given in 8.6% patients). Most patients received dexamethasone (77.5%), followed by methylprednisolone (45.6%) and prednisone (5.4%). Patients started corticosteroids on the median first day of hospitalization. Patients were concomitantly treated with remdesivir (54.1%) and low molecular weight heparins in prophylactic (20.9%), intermediate (33.9%) and therapeutic doses (43%).

Median age of patients was 65 years, interquartile range (interquartile range [IQR] 56–72). Median Charlson comor-

bidity index was 3 points, IQR (1–4). There were 63.5% male and 36.5% female patients. Intrahospital mortality, mechanical ventilation (MV), venous thromboembolism (VTE), major bleeding (MB) and bacterial blood stream infection (BSI) rates in 14-days survivors were 16.8%, 20.3%, 8%, 3.2% and 10.4%, respectively. Patients with longer duration of corticosteroid treatment were significantly older (median 66 vs. 64 yr, $p < 0.001$), had slightly higher comorbidity burden (median Charlson comorbidity index 3 vs. 3 points, $p < 0.001$) and required higher intensity of oxygen supplementation at admission (median oxygen flow 10 vs. 5 L/min) but did not significantly differ regarding sex nor remdesivir exposure ($p > 0.05$ for both analyses).

Corticosteroid use > 14 days was significantly associated with higher mortality (29% vs. 12.9%; hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.91–3.66; log-rank test $p < 0.001$) as shown in Figure 1A. This association persisted (HR, 1.49; 95% CI, 1.11–2.01; $p = 0.007$) in multivariate Cox regression model adjusted for age ($p < 0.001$), sex ($p = 0.087$), required oxygen supplementation at admission ($p < 0.001$), Charlson comorbidity index ($p = 0.002$) and remdesivir use ($p = 0.552$). Corticosteroid use > 14 days was also significantly associated with higher rates of MV (34.1% vs. 15.8%, chi-squared test $p < 0.001$), VTE (16.3% vs. 5.3%, chi-squared test $p < 0.001$), MB (5.8% vs. 2.3%, chi-squared test $p = 0.005$) and BSI (17% vs. 8.2%, chi-squared test $p < 0.001$).

In contrast to report by Kim et al. [1], our data suggest that prolonged corticosteroid use in severe and critical COVID-19 patients may result in higher mortality and higher rates of complications of corticosteroid treatment (VTE, MB, BSI). Different conclusions could be obtained from our dataset as well, if conditional 14-days survival time was not imple-




Figure 1. (A) Survival post 14-days after hospital admission stratified by duration of corticosteroid (CS) use (≤ 14 and > 14 days of treatment). (B) Survival post hospital admission without implementing 14-days survival time landmark.

mented (Fig. 1B). However, results based on a post-baseline definition of a variable that cannot be achieved if the patients died previously, are inevitably biased towards more favorable outcomes associated with having the designated feature. This is also known as the phenomenon termed immortalization or immortal time bias [2]. Thus, we would like to suggest the authors to evaluate whether associations observed in their study persist after implementing mandatory 14-day survival condition to further clarify whether prolonged corticosteroid use may indeed benefit the patients.

REFERENCES

1. Kim JH, Na YS, Lee SJ, et al. Corticosteroid outcome may be dependent of duration of use in severe COVID-19. *Korean J Intern Med* 2023;38:382-392.
2. Skelin M, Lucijanic M. Longer survival with anti-programmed cell death 1 and development of cutaneous toxic effects, an expected association. *JAMA Oncol* 2019;5:1642.

Received : October 21, 2023

Revised : November 12, 2023

Accepted : November 13, 2023

Correspondence to

Marko Lucijanic, M.D. Ph.D.

Department of Hematology, University Hospital Dubrava, School of Medicine University of Zagreb, Av. Gojka Suska 6, 10000 Zagreb, Croatia

Tel: +385-1-290-2444

E-mail: markolucijanic@yahoo.com

<https://orcid.org/0000-0002-1372-2040>

CRedit authorship contributions

Marko Lucijanic: conceptualization, methodology, investigation, validation, writing - original draft, writing - review & editing, supervision, project administration; Ivan Papis: methodology, investigation, validation, writing - original draft, writing - review & editing; Maja Ortner Hadziabdic: conceptualization, investigation, validation, writing - original draft, writing - review & editing, supervision

Conflicts of interest

The authors disclose no conflicts.

Funding

None

Ethical approval

The study was approved by the University Hospital Dubrava Review Board (Nm. 2021/1410-01). The study was conducted in accordance with the Declaration of Helsinki.

Data availability

Data can be obtained from the corresponding author per reasonable e-mail request.